BIOFRONTERA AG (B8FK.DE) Stock Overview
Europe - FRA:B8FK - DE000A4BGGM7 - Common Stock
B8FK.DE Key Statistics, Chart & Performance
The current stock price of B8FK.DE is 2.67 EUR. In the past month the price increased by 0.38%. In the past year, price decreased by -3.61%.
B8FK.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 51.52 | 678.33B | ||
| LLY.DE | ELI LILLY & CO | 51.52 | 678.23B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.87 | 444.61B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.48 | 397.91B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.32 | 394.53B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.45 | 248.76B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.92 | 239.54B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 15.01 | 218.75B | ||
| NOT.DE | NOVARTIS AG-REG | 14.96 | 218.05B | ||
| 1SAN.MI | SANOFI | 14.49 | 217.12B | ||
| SNW.DE | SANOFI | 14.45 | 216.58B | ||
| SAN.PA | SANOFI | 14.44 | 216.39B |
Related stock screener links
About B8FK.DE
Company Profile
Biofrontera AG engages in the research, development, and marketing of dermatological products. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 83 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Company Info
BIOFRONTERA AG
Hemmelrather Weg 201
Leverkusen NORDRHEIN-WESTFALEN DE
Employees: 83
Phone: 49214876320
BIOFRONTERA AG / B8FK.DE FAQ
What does BIOFRONTERA AG do?
Biofrontera AG engages in the research, development, and marketing of dermatological products. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 83 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
What is the current price of B8FK stock?
The current stock price of B8FK.DE is 2.67 EUR.
Does B8FK stock pay dividends?
B8FK.DE does not pay a dividend.
How is the ChartMill rating for BIOFRONTERA AG?
B8FK.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is BIOFRONTERA AG (B8FK.DE) stock traded?
B8FK.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the market capitalization of B8FK stock?
BIOFRONTERA AG (B8FK.DE) has a market capitalization of 16.23M EUR. This makes B8FK.DE a Nano Cap stock.
Can you provide the ownership details for B8FK stock?
You can find the ownership structure of BIOFRONTERA AG (B8FK.DE) on the Ownership tab.
B8FK.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to B8FK.DE. When comparing the yearly performance of all stocks, B8FK.DE is a bad performer in the overall market: 63.35% of all stocks are doing better.
B8FK.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to B8FK.DE. While B8FK.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
B8FK.DE Financial Highlights
Over the last trailing twelve months B8FK.DE reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -8.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.27% | ||
| ROE | -18% | ||
| Debt/Equity | 0.01 |
B8FK.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 124.55% and a revenue growth 22.18% for B8FK.DE